DNA Vaccination/Genetic Vaccination

1. Front Matter

   Pages I-XVII

   PDF

2. DNA Vaccine Strategies for the Treatment of Cancer

   • P. A. Benton, R. C. Kennedy

   Pages 1-20

3. Vaccination Against Pathogenic Cells by DNA Inoculation

   • B. Wang, A. P. Godillot, M. P. Madaio, D. B. Weiner, W. V. Williams

   Pages 21-35

4. DNA Vaccination as an Approach to Malaria Control: Current Status and Strategies

   • D. L. Doolan, R. C. Hedstrom, M. J. Gardner, M. Sedegah, H. Wang, R. A. Gramzinski et al.

   Pages 37-56

5. DNA-Based Immunization Against Hepatitis B: Experience with Animal Models

   • H. L. Davis

   Pages 57-68

6. DNA Vaccines and Immunity to Herpes Simplex Virus

   • B. T. Rouse, S. Nair, R. J. D. Rouse, Z. Yu, N. Kuklin, K. Karem et al.

   Pages 69-78

7. Humoral and Cellular Immune Responses to Herpes Simplex Virus-2 Glycoprotein D Generated by Facilitated DNA Immunization of Mice

   • C. J. Pachuk, R. Arnold, K. Herold, R. B. Ciccarelli, T. J. Higgins

   Pages 79-89

8. Nucleic Acid Vaccines: Veterinary Applications

   • L. A. Babiuk, P. J. Lewis, S. Drunen Little-Van van den Hurk, S. Tikoo, X. Liang

   Pages 90-106

9. Nucleic Acid-Based Vaccines as an Approach to Immunization Against Human Immunodeficiency Virus Type-1

   • M. L. Bagarazzi, J. D. Boyer, V. Ayyavoo, D. B. Weiner

   Pages 107-143

10. Human Immunodeficiency Virus Immunotherapy Using a Retroviral Vector

    • J. F. Warner, D. J. Jolly, J. Merritt

    Pages 145-160

11. Developing DNA Vaccines Against Immunodeficiency Viruses

    • S. Lu

    Pages 161-173

12. DNA Plasmid Based Vaccination Against the Oncogenic Human T Cell Leukemia Virus Type 1

    • M. G. Agadjanyan, B. Wang, S. B. Nyland, D. B. Weiner, K. E. Ugen

    Pages 175-192

13. Back Matter

    Pages 193-201

    PDF

Genetic / DNA immunization represents a novel approach to vaccine and immune therapeutic development. The direct injec­ tion of nucleic acid expression cassettes into a living host results in a limited number of its cells becoming factories for production of the introduced gene products. This host-inappropriate gene expression has important immunological consequences, resulting in the specific immune activation of the host against the gene­ delivered antigen. The recent demonstration by a number of laboratories that the induced immune responses are functional in experimental models against both specific infectious diseases and cancers is likely to have dramatic consequences for the develop­ ment of a new generation of experimental vaccines and immune therapies. This technology has the potential to enable the pro­ duction of vaccines and immune-based therapies that are not only effective immunologically but are accessible to the entire world (rather than just to the most developed nations). Vaccine Development Vaccination against pathogenic microorganisms represents one of the most important advances in the history of medicine. Vaccines, including those against polio, measles, mumps, rubella, hepatitis A, hepatitis B, pertussis and other diseases, have dramatically improved and protected more human lives than any other avenue of modern medicine. The vaccine against smallpox, for example, has been so successful that it is now widely believed that this malicious killer, responsible for more deaths in the twentieth century than World Wars I and II combined, has been removed from the face of the earth.

• AIDS
• DNA
• autoimmune disease
• cancer
• gene therapy
• hepatitis
• hepatitis B
• immunodeficiency
• immunotherapy
• infection
• malaria
• protein
• vaccination
• vaccine
• virus

• Department of Microbiology and Immunology Center for Neurobiology, Thomas Jefferson University, Philadelphia, USA

  Hilary Koprowski

• Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine Hospital of the University of Pennsylvania, Philadelphia, USA

  David B. Weiner

Policies and ethics